The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center - 05/12/22
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Background |
Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality among immunocompromised patients. Tixagevimab–cilgavimab (Tix-Cil) is a combination of 2 monoclonal antibodies approved for the prevention of COVID-19 complications in this high-risk group.
Methods |
We retrospectively reviewed the charts of patients who received Tix-Cil during the Omicron variant period (January 17 to April 23, 2022), with a follow-up period until May 24, 2022. We collected data about patient underlying comorbidities and post Tix-Cil COVID-19 infections, deaths, and hospitalizations.
Results |
There were 463 patients with a median age of 68 years, of which 51% were male, 79% White, 13.2% Hispanic, 1.7% Black/African American, and 5.8% identified as Other. A total of 18% had undergone a solid organ transplantation or hematopoietic stem cell transplantation. Only 6/98 (6.1%) had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detected by polymerase chain reaction (PCR) at a median 48 days (interquartile range [IQR] 27.5, 69) follow-up. Forty-two patients (9.1%) were hospitalized, and 4 (0.9%) died, but none were attributed to COVID-19 or Tix-Cil. One hospitalized patient had an incidental, asymptomatic, positive SARS-CoV 2 by PCR. The median days from Tix-Cil administration to non-COVID-19-related hospitalization and death were 30 (IQR 17, 55) and 53 (IQR 18, 91), respectively.
Conclusion |
Tix-Cil provides protection against COVID-19 complications in immunocompromised patients with suboptimal immune responses to vaccines.
El texto completo de este artículo está disponible en PDF.Keywords : COVID-19, Immunocompromised host, Tixagevimab–cilgavimab
Esquema
| Funding: None. |
|
| Conflicts of Interest: None. |
|
| Authorship: MMA-O, TTZ, and BT helped in the conceptualization, study design, and writing the manuscript. MMA-O, TTZ, ABG, SEK, and AEM helped in the data collection and review of the manuscript. |
Vol 136 - N° 1
P. 96-99 - janvier 2023 Regresar al número
Artículo precedente
- ‘Bushfire Season’ in Australia: Determinants of Increases in Risk of Acute Coronary Syndromes and Takotsubo Syndrome
- Gao Jing Ong, Alexander Sellers, Gnanadevan Mahadavan, Thanh H. Nguyen, Matthew I. Worthley, Derek P. Chew, John D. Horowitz
- Prosthetic Joint Infections of the Hip and Knee Among the Elderly: A Retrospective Study
- Anne Spichler-Moffarah, Lee E. Rubin, Jenna A. Bernstein, Jane O'Bryan, Erik McDonald, Marjorie Golden
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.